1460-2407 < 1462-0324 < 1462-0332

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by 1462-0324

Number of relevant bibliographic references: 93.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000755 (2019)	Shirly Frizinsky [Israël] ; Soad Haj-Yahia [Israël] ; Diti Machnes Maayan [Israël] ; Yulia Lifshitz [Israël] ; Ramit Maoz-Segal [Israël] ; Irean Offengenden [Israël] ; Mona Kidon [Israël] ; Nancy Agmon-Levin [Israël]	The innate immune perspective of autoimmune and autoinflammatory conditions
000A80 (2019)	Sophia C. Weinmann [États-Unis] ; David S. Pisetsky [États-Unis]	Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
000A86 (2019)	Neil M. Steven [Royaume-Uni] ; Benjamin A. Fisher [Royaume-Uni]	Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
000A87 (2019)	Jan Leipe [Allemagne] ; Xavier Mariette [France]	Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
000C37 (2019)	Mark Kacar [Royaume-Uni] ; Shelly Pathak [Royaume-Uni] ; Sinisa Savic [Royaume-Uni]	Hereditary systemic autoinflammatory diseases and Schnitzler’s syndrome
000C49 (2019)	Matthew Hutchinson [Royaume-Uni] ; Rachel S. Tattersall [Royaume-Uni] ; Jessica J. Manson [Royaume-Uni]	Haemophagocytic lymphohisticytosis—an underrecognized hyperinflammatory syndrome
000D25 (2019)	Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raimon Sanmarti [Espagne] ; Min Bao [États-Unis] ; Jenny Devenport [États-Unis] ; Attila Pethö-Schramm [Suisse]	Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
000D43 (2019)	Ernest H. Choy	Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
000E72 (2019)	Marie Kostine ; Marie-Elise Truchetet ; Thierry Schaeverbeke	Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
000F75 (2019)	Sebastiaan J. Vastert [Pays-Bas] ; Yvan Jamilloux [France] ; Pierre Quartier [France] ; Sven Ohlman [Suède] ; Lisa Osterling Koskinen [Suède] ; Torbjörn Kullenberg [Suède] ; Karin Franck-Larsson [Suède] ; Bruno Fautrel [France] ; Fabrizio De Benedetti [Italie]	Anakinra in children and adults with Still’s disease
001023 (2019)	Rinie Geenen [Pays-Bas] ; Emma Dures [Royaume-Uni]	A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review
001189 (2018)	Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raim N Sanmarti [Espagne] ; Min Bao [États-Unis] ; Corrado Bernasconi [Suisse] ; Attila Pethö-Schramm [Suisse]	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
001198 (2018)	Lianne Kearsley-Fleet [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Diederik De Cock [Royaume-Uni] ; Eileen Baildam [Royaume-Uni] ; Helen E. Foster [Royaume-Uni] ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]	Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
001292 (2018)	Clément Lahaye [France] ; Zuzana Tatar [France] ; Jean-Jacques Dubost [France] ; Anne Tournadre [France] ; Martin Soubrier [France]	Management of inflammatory rheumatic conditions in the elderly
001489 (2018)	Inge C. Olsen [Norvège] ; Elisabeth Lie [Norvège] ; Radu Vasilescu [Belgique] ; Gene Wallenstein [États-Unis] ; Sander Strengholt [Pays-Bas] ; Tore K. Kvien [Norvège]	Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
001492 (2018)	Anja Sophie Schmid [Suisse] ; Teresa Hemmerle [Suisse] ; Francesca Pretto [Suisse] ; Anja Kipar [Suisse] ; Dario Neri [Suisse]	Antibody-based targeted delivery of IL-4 synergizes with DXM but not other therapeutics for the reduction of inflammation in arthritis
001505 (2018)	François Montastruc [Canada, France] ; Christel Renoux [Canada] ; Sophie Dell Niello [Canada] ; Teresa A. Simon [États-Unis] ; Laurent Azoulay [Canada] ; Marie Hudson [Canada] ; Samy Suissa [Canada]	Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study
001534 (2017-07-14)	Jacques Morel [France] ; Arnaud Constantin [France] ; Gabriel Baron [France] ; Emmanuelle Dernis [France] ; René-Marc Flipo [France] ; Stéphanie Rist [France] ; Bernard Combe [France] ; Jacques-Eric Gottenberg [France] ; Thierry Schaeverbeke [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Maxime Dougados [France] ; Alain Saraux [France] ; Xavier Mariette [France] ; Philippe Ravaud [France] ; Jean Sibilia [France]	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE
001535 (2017-04-20)	Guillermo Carvajal Alegria [France] ; Valérie Devauchelle-Pensec [France] ; Yves Renaudineau [France] ; Alain Saraux [France] ; Jacques-Olivier Pers [France] ; Divi Cornec [France]	Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica.
001664 (2017)	Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raim N Sanmarti [Espagne] ; Min Bao [États-Unis] ; Corrado Bernasconi [Suisse] ; Attila Pethö-Schramm [Suisse]	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
001729 (2017)	Michael B. Arnold [Canada] ; Dinesh Khanna [États-Unis] ; Christopher P. Denton [Royaume-Uni] ; Jacob M. Van Laar [Pays-Bas] ; Tracy M. Frech [États-Unis] ; Marina E. Anderson [Royaume-Uni] ; Murray Baron [Canada] ; Lorinda Chung [États-Unis] ; Gerhard Fierlbeck [Allemagne] ; Santhanam Lakshminarayanan [États-Unis] ; Yannick Allanore [France] ; Gabriela Riemekasten [Allemagne] ; Virginia Steen [États-Unis] ; Ulf Müller-Ladner [Allemagne] ; Helen Spotswood [Royaume-Uni] ; Laura Burke [Royaume-Uni] ; Jeffrey Siegel ; Angelika Jahreis ; Daniel E. Furst [États-Unis] ; Janet E. Pope [Canada]	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1462-0324" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1462-0324" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1462-0324
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021